Merck, Inc.
🇺🇸United States
A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)
Phase 1
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: MAALOX (MAL)
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT01930045
Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)
Phase 1
Completed
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo for MK-8892
- First Posted Date
- 2013-08-21
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 23
- Registration Number
- NCT01926509
A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)
Phase 1
Withdrawn
- Conditions
- Asthma
- Interventions
- Drug: Placebo to MK-8351Drug: Low-Dose MK-8351Drug: High-Dose MK-8351
- First Posted Date
- 2013-08-20
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT01926002
Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)
Phase 4
Completed
- Conditions
- Rotavirus Disease
- Interventions
- Biological: RotaTeq™ (V260)Biological: DTP-IPV
- First Posted Date
- 2013-08-20
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 192
- Registration Number
- NCT01926015
Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)
- First Posted Date
- 2013-08-08
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 36
- Registration Number
- NCT01919125
Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)
Phase 1
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 34
- Registration Number
- NCT01907724
Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
Phase 2
Completed
- Conditions
- Non Small Cell Lung Cancer (NSCLC)
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2013-07-23
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1034
- Registration Number
- NCT01905657
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
Phase 3
Completed
- Conditions
- Melanoma
- Interventions
- Biological: IpilimumabBiological: Pembrolizumab
- First Posted Date
- 2013-05-31
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 834
- Registration Number
- NCT01866319
A Study to Evaluate the Safety and Use of Human Rhinovirus in Healthy and Asthmatic Participants (MK-0000-218)
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Biological: RV16UBDrug: LABA
- First Posted Date
- 2013-05-31
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 59
- Registration Number
- NCT01866306
A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)
Phase 3
Terminated
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 65
- Registration Number
- NCT01863667